Fig.4
EGCG/RSVL inhibits cGAS activation. a–d ARPE-19 cells were transfected with HT-DNA (2 μg mL−1) for 6 h, following a 3-h pretreatment with EGCG or RSVL as indicated, qPCR analysis of IFNB mRNA levels (a and c). Immunoblot analysis of expression levels of proteins, EGCG (20 μM) or RSVL (40 μM) were respectively used (b and d). e Immunoblot analysis of indicated proteins of ARPE-19 and hTERT RPE-1. f, g Pull-down assays with EGCG/RSVL-conjugated Sepharose beads in ARPE-19 cells. EGCG/RSVL-binding proteins were analyzed by immunoblotting with indicated antibodies (f and g). h, i Cell viability of ARPE-19 cells treated by EGCG (h) or RSVL (i) as indicated. Data are mean ± s.e.m. of three independent experiments (a, c, h and i), *P < 0.05, **P < 0.01, two-tailed t-test (a and c). GAPDH (b, d, e, f and g), loading controls. Data are representative of at least two independent experiments